基于肠-关节轴机制探讨益生菌对类风湿性关节炎的疗效研究

注册号:

Registration number:

ChiCTR2500109356 

最近更新日期:

Date of Last Refreshed on:

2025-09-17 14:36:41 

注册时间:

Date of Registration:

2025-09-17 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

基于肠-关节轴机制探讨益生菌对类风湿性关节炎的疗效研究

Public title:

A study on the therapeutic effect of probiotics on rheumatoid arthritis based on the gut-joint axis mechanism

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于肠-关节轴机制探讨益生菌对类风湿性关节炎的疗效研究

Scientific title:

A study on the therapeutic effect of probiotics on rheumatoid arthritis based on the gut-joint axis mechanism

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

徐威 

研究负责人:

徐威 

Applicant:

Xu Wei 

Study leader:

Xu Wei 

申请注册联系人电话:

Applicant telephone:

+86 158 5811 7403

研究负责人电话:

Study leader's
telephone:

+86 158 5811 7403

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

xuwei19870903@163.com

研究负责人电子邮件:

Study leader's E-mail:

xuwei19870903@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

浙江省杭州市淳安县千岛湖镇星月湾6-2-503

研究负责人通讯地址:

浙江省杭州市淳安县千岛湖镇星月湾6-2-503

Applicant address:

Room 503, Building 6-2, Xingyuewan, Qiandaohu Town, Chun 'an County, Hangzhou City, Zhejiang Province

Study leader's address:

Room 503, Building 6-2, Xingyuewan, Qiandaohu Town, Chun 'an County, Hangzhou City, Zhejiang Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

淳安县中医院

Applicant's institution:

Chun 'an County Hospital of Traditional Chinese Medicine

研究负责人所在单位:

淳安县中医院

Affiliation of the Leader:

Chun 'an County Hospital of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

伦审研2024第002号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

浙江省淳安县中医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Chun 'an County Hospital of Traditional Chinese Medicine, Zhejiang Province

伦理委员会批准日期:

Date of approved by ethic committee:

2024-06-05 00:00:00

伦理委员会联系人:

陈剑

Contact Name of the ethic committee:

Chen Jian

伦理委员会联系地址:

浙江省杭州市淳安县千岛湖镇新安西路1号

Contact Address of the ethic committee:

No. 1, Xin 'an West Road, Qiandaohu Town, Chun 'an County, Hangzhou City, Zhejiang Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 137 7788 1060

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

淳安县中医院

Primary sponsor:

Chun 'an County Hospital of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

浙江省杭州市淳安县千岛湖镇新安西路1号

Primary sponsor's address:

No. 1, Xin 'an West Road, Qiandaohu Town, Chun 'an County, Hangzhou City, Zhejiang Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

浙江

市(区县):

淳安

Country:

China

Province:

Zhejiang

City:

Chun 'an

单位(医院):

淳安县中医院

具体地址:

浙江省杭州市淳安县千岛湖镇新安西路1号

Institution
hospital:

Chun 'an County Hospital of Traditional Chinese Medicine

Address:

No. 1, Xin 'an West Road, Qiandaohu Town, Chun 'an County, Hangzhou City, Zhejiang Province

经费或物资来源:

单位配套

Source(s) of funding:

Unit supporting facilities

研究疾病:

类风湿关节炎  

Target disease:

RA(rheumatoid arthritis)

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

通过研究和整理益生菌治疗类风湿关节炎的规范性病历文本,观察益生菌治疗RA的有效性及安全性。为基层类风湿性关节炎的患者提供一条简便、价廉、有效的治疗途径。  

Objectives of Study:

By studying and organizing the standardized medical record texts of probiotics in the treatment of rheumatoid arthritis, the efficacy and safety of probiotics in the treatment of RA were observed. Provide a simple, inexpensive and effective treatment option for patients with rheumatoid arthritis at the grassroots level.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

(1)不符合纳入标准者; (2)并发有其他风湿性疾病如系统性红斑狼疮,或患有影响关节功能的特殊类型的关节炎者; (3)合并严重的心血管、肝、肾和造血系统等原发疾病的,或者精神异常和肿瘤患者; (4)长期依赖激素和生物制剂者; (5)怀孕期间、哺乳期妇女、酒精过敏史或有明确药食物过敏史; (6)研究者通过评估,认为误纳入者,存在有任何不满足入选要求者。

Exclusion criteria:

(1) Those who do not meet the inclusion criteria; (2) Those who have concurrent other rheumatic diseases such as systemic lupus erythematosus, or suffer from special types of arthritis that affect joint function; (3) Patients with severe primary diseases of the cardiovascular, liver, kidney and hematopoietic systems, or those with mental disorders and tumors; (4) Those who have long relied on hormones and biological agents; (5) Pregnant women, lactating women, those with a history of alcohol allergy or a clear history of drug or food allergy; (6) The researchers, through assessment, found that those who were mistakenly included did not meet any of the inclusion requirements.

研究实施时间:

Study execute time:

From 2024-11-01 00:00:00 To 2026-10-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-03-01 00:00:00 To 2026-03-31 00:00:00

干预措施:

Interventions:

组别:

治疗组

样本量:

30

Group:

treatment group

Sample size:

干预措施:

治疗组在基础治疗上再予益生菌治疗。益生菌选用复合乳酸菌肠溶胶囊。治疗6周为1疗程。

干预措施代码:

Intervention:

The treatment group was given probiotic treatment in addition to the basic treatment. The probiotics selected are complex lactic acid bacteria enteric-coated capsules. A course of treatment lasts for 6 weeks.

Intervention code:

组别:

对照组

样本量:

30

Group:

control group

Sample size:

干预措施:

予MTX(每次10 mg,口服,1次/周)为基础治疗。

干预措施代码:

Intervention:

The treatment was based on MTX (10 mg each time, orally, once a week).

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

浙江省 

市(区县):

淳安县 

Country:

China

Province:

Zhejiang

City:

Chun 'an

单位(医院):

淳安县中医院 

单位级别:

三级 

Institution
hospital:

Chun 'an County Hospital of Traditional Chinese Medicine

Level of the institution:

Tertiary

测量指标:

Outcomes:

指标中文名:

实验室相关指标(血清 ESR、RF、CRP 水平)

指标类型:

主要指标

Outcome:

Laboratory-related indicators (serum ESR, RF, CRP levels)

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

患者视觉模拟评分

指标类型:

次要指标

Outcome:

Patient Visual Analogue Scale score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 65 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

简单随机,请专业统计人员(余晓蓉)用 SAS 统计分析系统 PROCPLAN 过程语句,生成随机数字表,按随机数字表编制随机分配卡

Randomization Procedure (please state who generates the random number sequence and by what method):

For simple randomization, please have a professional statistician (Yu Xiaorong) use the PROCPLAN process statement of the SAS statistical analysis system to generate a random number table and compile the random allocation card according to the random number table

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

对结局评估者和统计人员设盲

Blinding:

Blinding of outcome assessors and statisticians

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

原始数据将在研究结束后12个月内进行整理与脱敏处理后通过医学研究数据共享平台中国临床试验注册中心(ChiCTR)公开核心数据集

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

The raw data will be collated and desensitized within12 months after the end of the study, and the core dataset is planned to be made publicly available through the medical research data sharing platform China Clinical Trial Registry (ChiCTR)

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表和电子采集和管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

(Case Record Form, CRF),(Electronic Data Capture, EDC),

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-09-17 14:36:24